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Background. M-M-RTMII (MMRII; Merck & Co) is currently the only measles-mumps-rubella (MMR)
vaccine licensed in the United States. Another licensed vaccine would reinforce MMR supply. This study
assessed the immunogenicity of a candidate vaccine (PriorixTM, GlaxoSmithKline Vaccines [MMR-RIT]) when
used as a first dose among eligible children in the United States.
Methods. In this exploratory Phase-2, multicenter, observer-blind study, 1220 healthy subjects aged 12–15
months were randomized (3:3:3:3) and received 1 dose of 1 of 3 MMR-RIT lots with differing mumps virus
titers (MMR-RIT-1 [4.8 log10]; MMR-RIT-2 [4.1 log10]; MMR-RIT-3 [3.7 log10] CCID50) or MMRII
co-administered with hepatitis A vaccine (HAV), varicella vaccine (VAR) and 7-valent pneumococcal conjugate
vaccine (PCV7). Immune response to measles, mumps, and rubella viruses was evaluated at Day 42
post-vaccination. Incidence of solicited injection site, general, and serious adverse events was assessed.
Results. Seroresponse rates for MMR vaccine viral components in MMR-RIT lots were 98.3–99.2%
(measles), 89.7–90.7% (mumps), and 97.5–98.8% (rubella), and for MMRII were 99.6%, 91.1%, and 100%,
respectively. Immune responses to HAV, VAR, and PCV7 were similar when co-administered with any of the
3MMR-RIT lots orMMRII. Therewere no apparent differences in solicited or serious adverse events among the
4 groups.
Conclusions. Immune responses were above threshold levels for projected protection against the 3 viruses from
MMR-RIT lots with differing mumps virus titers. MMR-RIT had an acceptable safety profile when
co-administered with HAV, VAR, and PCV7.
Clinical Trials Registration. NCT00861744; etrack; 111870
Key words. co-administration; immunogenicity; measles; mumps; rubella.
INTRODUCTION
Despite the successful introduction of routine immuniza-
tion with combined live attenuated measles-mumps-
rubella (MMR) vaccines in the 1970s [1], outbreaks and
generally increased prevalence of mumps and measles
are still noted among the vaccinated and unvaccinated
populations, respectively, across the United States [2–4].
Maintenance of high vaccine coverage rates remains an es-
sential component of efforts to control these diseases. A
2-dose MMR vaccination schedule is recommended in
the United States. Children receive dose-1 at 12–15 months
concomitantly with other recommended vaccines, includ-
ing hepatitis A vaccine (HAV), varicella vaccine (VAR),
and pneumococcal conjugate vaccine (PCV) [5–8]. MMR
dose-2 is administered at age 4–6 years to induce immune
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responses in those who fail to respond to the initial dose.
Two-dose catch-up schedules, with a minimum 4-week in-
terval betweenMMR doses, are recommended for children
and adolescents who miss the first dose [9]. As Merck’s
M-M-RTMII (MMRII), a human serum albumin-free
vaccine, is currently the only MMR vaccine licensed in
the United States, any interruption in its availability
would pose a critical public health risk. Therefore,
GlaxoSmithKline Vaccines is currently evaluating its triva-
lent MMR vaccine PriorixTM (MMR-RIT) for use in the
United States. MMR-RIT is routinely given in over 100
countries from the second year of life onwards [10]. The
formulation of MMR-RIT used in this study does not con-
tain human serum albumin, thereby minimizing any theo-
retical risk of microbial contamination as compared to
previous formulations [11].This formulation is also consis-
tent with the recommendation from the European
Medicines Agency to eliminate the use of blood-derived
products of human origin [12, 13].
This Phase-2 exploratory study assessed immunologic
responses to 3 lots of MMR-RIT (containing a range of
mumps virus titers) and to MMRII used as a first dose in
12–15-month-old children in the United States. The study
was used as a preliminary evaluation of the minimum effec-
tive mumps virus titer for the candidate vaccine to allow
planning of a Phase-3 study, and was used also to generate
preliminary data on the safety and immunogenicity of co-
administration of MMR-RIT with routine childhood vac-
cines: VAR, HAV, and 7-valent PCV (PCV7).
METHODS
This randomized, observer-blind, Phase-2 study was con-
ducted at 51 centers in the Unites States in accordance
with the Declaration of Helsinki and Good Clinical Prac-
tice guidelines. The study was approved by a national, re-
gional, or investigational center institutional review board
or independent ethics committee. Written informed con-
sent was obtained from parents/guardians before enroll-
ment. The study consisted of an active phase (immediate
post-vaccination interval; Days 0–42), an extended safety
follow-up phase (Days 43–180), and an antibody persis-
tence phase ending approximately 2 years post-vaccination.
Only the results of a planned analysis conducted for immu-
nogenicity and safety data from the active phase are
reported here.
Eligible healthy 12- to 15-month-old male and female
subjects had not been previously immunized against (and
had no previous history of ) measles, mumps, rubella, var-
icella, and hepatitis A, and had received 3 doses of PCV7
within the first year of life (third dose administered 30
days before enrollment). Other key exclusion criteria in-
cluded: exposure to measles, mumps, rubella, or varicella
30 days before study start; previous (30 days before
study start) or planned administration of investigational
products during the study; administration of other vaccines
(except influenza and Haemophilus influenzae type b)
30 days before study vaccination until Day 42; chronic
immunosuppressants/immune-modifying drugs, polyclon-
al immunoglobulins, or blood products received 6
months before study vaccination; immunosuppressive or
immunodeficient conditions; contraindication to vaccina-
tion; a history of neurologic disorders or seizures; acute dis-
ease at enrollment; and severe chronic illness or major
congenital defects.
Subjects visited the study site at Days 0, 42, 180, 365,
and 730. At Day 0 (Visit 1), subjects were randomized
using a blocking scheme (3:3:3:[1:1:1] ratio) to 1 of 4 par-
allel treatment groups: 3 groups received a single dose of
1 of 3 MMR-RIT lots (containing either high [MMR-RIT-1],
medium [MMR-RIT-2], or low [MMR-RIT-3] RIT 4385
mumps strain titers); the fourth group received a single
dose of 1 of 3 commercial lots of MMRII (Merck & Co
Inc. [14]) (Table 1). The randomization list was generated
at GlaxoSmithKline Biologicals using SAS® software.
Treatment allocation was performed at the investigator
site via a central internet-based randomization system.
Subjects concomitantly received a single dose each
of HAV (HavrixTM, GlaxoSmithKline Vaccines [15]),
VAR (VarivaxTM, Merck & Co. Inc. [16]), and PCV7
(PrevnarTM, Wyeth [17]) at Day 0. Immune response
against measles, mumps, and rubella viruses was assessed
at Day 42 (Visit 2). MMR-RIT or MMRII were adminis-
tered subcutaneously into the upper right arm, VAR subcu-
taneously into the upper left arm, and HAV and PCV7
Table 1. Formulation of 3 Lots of Candidate MMR-RIT
(Measles, Mumps, Rubella) Vaccine and Commercially
Available Comparator Vaccine (MMRII, Merck & Co., Inc.)
Vaccine Lot Number(s)
Log10 CCID50
Measlesa Mumpsb Rubellac
MMRII 1291X 4.0 4.8 4.2
1255X 3.9 4.8 4.0
1362X 3.8 4.8 4.1
MMR-RIT-1 AMJRB721A 3.8 4.8 (high) 3.9
MMR-RIT-2 DMJRA002A 4.1 4.1 (medium) 3.9
MMR-RIT-3 DMJRA003A 4.0 3.7 (low) 4.1
Abbreviation: CCID50, Median cell culture infective dose.
Note: All CCID50 values for vaccine components of MMRII and MMR-RIT
were determined by GlaxoSmithKline.
aMeasles was Schwarz strain for GlaxoSmithKline vaccines and Moraten
Edmonston-Enders strain for MMRII.
bMumps was RIT 4385 strain for GlaxoSmithKline vaccines and Jeryl Lynn for
MMRII.
cRubella strain was the same for MMRII and each MMR-RIT (ie, Wistar
RA 27/3).
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intramuscularly into the left and right thighs, respectively.
A second HAV dose was administered at Day 180 (Visit 3).
Vaccine recipients, parents/guardians, and those responsi-
ble for evaluation of study endpoints were blinded to study
treatment. Vaccine reception, storage, preparation, recon-
stitution, and administration were performed by study per-
sonnel who did not participate in outcome evaluation.
Immunogenicity
Blood for antibody determination was obtained from sub-
jects on Days 0 (pre-immunization), 42, 365, and 730.
Analysis of blood obtained at Days 365 and 730 for evalu-
ation of antibody persistence is ongoing and will be report-
ed separately. Sera were stored at -20°C until assayed in a
blinded manner at a central laboratory (GlaxoSmithKline
Biologicals, Rixensart, Belgium).Mumps virus antibody re-
sponse was determined using an in-house plaque-reduction
assay (GlaxoSmithKline Biologicals [18,19])via neutraliza-
tion of wild-type virus (Mu90LO1) in the presence of com-
plement and anti-human globulin. Immunoglobulin (Ig) G
antibodies to measles, rubella, and varicella-zoster virus
(VZV) were measured with commercial enzyme-linked im-
munosorbent assay (ELISA) (Enzygnost, Dade Behring,
Marburg GmbH, Germany); antibodies to hepatitis A
virus were determined in a randomized subset of 50% of
subjects. Antibodies to PCV7 pneumococcal serotypes
were measured in the remaining 50% with an in-house
ELISA (GlaxoSmithKline Biologicals [20]).Assay seronega-
tivity cut-off values for antibodies to vaccine viral antigens
were: measles <150 mIU/mL, mumps <24 ED50, rubella
<4 IU/mL, VZV <25 mIU/mL, hepatitis A <15 mIU/mL,
and Streptococcus pneumoniae <0.05 µg/mL. The serone-
gativity cut-offs evaluated in this study were determined
empirically as part of the assay validation protocol and
were accepted by the US Food and Drug Administration
(FDA). Post-vaccination seroresponses for MMR vaccine
viral antigens in initially seronegative subjects were defined
as antibody concentrations/titers of: measles200mIU/mL
[21]; mumps 51 ED50 (no known correlate of protection
threshold) and rubella 10 IU/mL [22]. The seroresponse
thresholds were accepted by the FDA as those defining
active immunization offering clinical benefit.
VAR response was defined as a post-vaccination anti-
body concentration 75 mIU/mL in initially seronegative
subjects. HAV response was defined as a post-vaccination
antibody concentration 15 mIU/mL in initially seronega-
tive subjects, or a 2-fold increase in the pre-vaccination
antibody concentration in initially seropositive subjects.
Reactogenicity and Safety
Reactogenicity and safety were assessed at each visit and
via subject diary cards completed by parents/guardians.
Solicited injection site symptoms (pain, redness, swelling
for study vaccines only) were recorded from Days 0–3.
Solicited general symptoms (fever, rash, parotid/salivary
gland swelling, febrile convulsions, irritability/fussiness,
drowsiness, and loss of appetite), and unsolicited symp-
toms were recorded from Days 0–42. Serious adverse
events (SAEs) were recorded throughout the study. Fever
was assessed daily with a tympanic thermometer or rectally
if the tympanic reading indicated fever (38.0°C). For each
reported symptom, parents/guardians were asked what
medical attention (if any) the subject had received.
Statistics
This was a “hypothesis-generating” exploratory study con-
ducted to provide estimations of response rates, which will
be used to develop statistical criteria for a formal Phase-3
trial to support licensure of the candidate vaccine on the
basis of non-inferior immunogenicity compared to the li-
censed comparator. All analyses in this study were descrip-
tive, and no formal statistical comparison was prespecified.
Enrollment of 1200 subjects (300/group) was planned to
ensure 240 evaluable subjects/group. Subjects in the
MMRII group were randomized across 3 commercial
MMRII lots; no lot-by-lot analysis was done and results
were pooled. The primary analysis of immunogenicity
was conducted on the according-to-protocol (ATP) cohort
for immunogenicity, which included eligible subjects who
had received the study vaccine via the correct administra-
tion route and complied with study procedures, and who
were below the assay cut-off for at least 1 MMR vaccine
antigen at baseline, with pre-vaccination and post-vaccina-
tion serology results available. Safety analysis was per-
formed on the total vaccinated cohort (TVC), which
included all vaccinated subjects.
The primary endpoint was seroresponse rates for anti-
bodies to measles, mumps, and rubella viruses at Day 42;
the proportions of subjects with antibody concentration/
titer at or above specified assay cut-offs were calculated
with exact 95% confidence intervals (CIs) both pre- and
post-vaccination. Secondary endpoints included pre- and
post-vaccination (Day 42) antibody concentration/titers,
summarized by geometric mean concentrations/titers
(GMC/Ts) with 95% CI. Exploratory analyses included
standardized asymptotic 2-sided 95% CIs calculated for
group differences (MMR-RIT group minus MMRII) in
Day-42 seroresponse rates for antibodies to MMR viruses.
In addition, 95% CIs for GMC ratios (MMR-RIT:
MMRII) for antibodies to hepatitis A virus and PCV7
pneumococcal serotypes were obtained using an analysis
of covariance model on the logarithm10-transformed
Day-42 concentrations. For the safety analysis, the number
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and percentage of subjects reporting a symptom were cal-
culated with exact 95% CIs. Symptoms were categorized
according to intensity and relationship to study vaccine.
All data processing and analyses were performed using
SAS® version 9.2 (SAS Institute Inc., Cary, NC). Proc
StatXact 8.1 derived exact 95% CIs for a proportion with-
in a group as well as standardized asymptotic 95% CI for
the group difference in proportions.
RESULTS
Subject Disposition and Baseline Demography
The first subject was enrolled on June 3, 2009, and the last
visit of the active (43-day) phase was completed on July 21,
2010. Of 1259 enrolled subjects, 1224 were randomized
and 4 did not receive study vaccine. The TVC consisted
of 1220 subjects: MMR-RIT-1 (n = 304), MMR-RIT-2
(n = 304), MMR-RIT-3 (n = 304), and MMRII (n = 308).
Of these, 1117 completed Day 42 and 103 werewithdrawn
(Figure 1).
Overall, of 1220 subjects in the TVC, 1026 subjects were
included in the ATP-immunogenicity cohort (194 subjects
were excluded): MMR-RIT-1 (n = 261); MMR-RIT-2
(n = 254); MMR-RIT-3 (n = 251), and MMRII (n = 260).
Demographic characteristics of the 4 treatment groups were
comparable between the TVC and ATP-immunogenicity
cohorts. Mean (standard deviation) age in the TVC was
12.3 (0.71) months, 75.8% of subjects were white, and
51.1% were male. In the ATP-immunogenicity cohort,
100%, 86.2%, and 99.8%, of subjects were seronegative
for measles, mumps and rubella antibody, respectively,
before study vaccination; overall baseline seronegativity
rates were comparable across the 4 groups (Table 2).
Immunogenicity
Seroresponse to MMRVaccines.Measles virus seroresponse
rates were 98.3–99.2% for MMR-RIT groups and 99.6%
for the MMRII group; GMCs of measles virus antibodies
were >2500 mIU/mL in all 4 groups. Day-42 seroresponse
rates for mumps virus antibodies were 89.7% for
Figure 1.Disposition of subjects in the total vaccinated cohort (TVC) (enrolled = 1259 subjects, randomized = 1224 subjects, vaccinated = 1220 subjects). Abbreviations:
MMR, measles-mumps-rubella; SAE, serious adverse event; ATP, according-to-protocol.
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MMR-RIT-3 (low mumps titer), 90.6% for MMR-RIT-2
(medium mumps titer), 90.7% for MMR-RIT-1 (high
mumps titer), and 91.1% for MMRII. Mumps virus
antibody GMTs were at least 10-fold greater than the
assay cut-off for seronegativity in all 4 groups. Day-42
rubella virus seroresponse rates were 97.5–98.8% for
MMR-RIT groups and 100% for the MMRII group.
Observed rubella virus antibody GMCs for MMR-RIT
groups (68.2–77.7 IU/mL) and MMRII (89.4 IU/mL)
were above the assay seronegativity cut-off of 10 IU/mL
(Table 3).
Co-administration of VAR, HAV, and PCV7. Day-42
seroresponse rates for antibodies to VZV among initially
seronegative subjects when VAR was co-administered with
MMR-RIT or MMRII were 95.8–98.0%. GMCs for VZV
antibodies were >200 mIU/mL in all 4 groups. Day-42
response rates for antibodies to hepatitis A virus were 83.0–
89.3% among initially seronegative vaccinees across the
4 groups. Day-42 GMCs adjusted for baseline serostatus
for antibodies to hepatitis A virus or pneumococcal sero-
types appeared to be similar for all 4 groups, as shown by
calculated GMC ratios in Table 4.
Safety and Reactogenicity
Overall incidence of solicited and unsolicited symptoms in
the TVC (Days-0–42) was 80.9% (95% CI: 76.0; 85.2) for
MMR-RIT-1, 75.7% (70.4; 80.4) for MMR-RIT-2,
74.0% (68.7; 78.9) for MMR-RIT-3, and 75.3% (70.1;
80.0) for MMRII. The most frequently observed solicited
symptom (Days 0–3) at MMR-RIT and MMRII injection
sites was pain, reported in 24.5% of subjects in each
group (Table 5), although Grade-3 pain (subject cried
when the limb was moved/spontaneously painful) was re-
ported in1.5%. Two subjects (1 each in theMMR-RIT-2
and MMRII groups) had Grade-3 injection site swelling
(diameter >20 mm).
During Days 0–14, irritability or fussiness (overall inci-
dence, 51.3–63.6%) and drowsiness (38.5–47.0%) were
the most frequently reported solicited general symptoms
(Table 5). Incidence of fever (rectal temperature 38.0°C)
during Days 0–14 was 20.2–28.7% across the 4 groups;
fever >39.5°C occurred in 3.5% subjects in any group.
Incidence of fever requiring medical attention reported
during Days 0–14 in each group was as follows: 6.0%
(95% CI: 3.5; 9.4) for MMR-RIT-1, 8.0% (5.1; 11.9) for
MMR-RIT-2, 8.5% (5.5; 12.4) for MMR-RIT-3, and
6.9% (4.2; 10.5) forMMRII. Overall incidence of fever dur-
ing Days 0–42 was 36.4–37.8% for MMR-RIT groups and
30.7% forMMRII recipients (Table 5). For all groups, prev-
alence of fever peaked 5–12 days after study vaccination
(Figure 2); in an exploratory post hoc analysis, the observedT
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Table 3. Seroresponse Rates andGeometricMean Concentrations/Titers (GMC/Ts) for Antibodies toMeasles,Mumps, and Rubella Viruses at Day 42 in Initially Seronegative
Subjects (According-to-Protocol Cohort for Immunogenicity)
Measles (200 mIU/mL) Mumps (51 ED50) Rubella (10 IU/mL)
N
Seroresponse
GMC (95%
CI) N
Seroresponse
GMC
(95% CI) N
Seroresponse
GMC (95% CI)n (%) (95% CI)
% Diff. vs. MMRII
(95% CI) n (%) (95% CI)
% Diff. vs. MMRII
(95% CI) n (%) (95% CI)
% Diff. vs. MMRII
(95% CI)
MMR-RIT-1
247 245 (99.2) (97.1;
99.9)
−0.41 (−2.55; 1.50) 2799 (2545;
3078)
193 175 (90.7) (85.7;
94.4)
−0.47 (−6.42; 5.46) 242 (205; 287) 247 244 (98.8) (96.5;
99.7)
−1.21 (−3.51; 0.32) 72.2 (65.6; 79.6)
MMR-RIT-2
240 236 (98.3) (95.8;
99.5)
−1.27 (−3.85; 0.74) 2878 (2607;
3178)
202 183 (90.6) (85.7;
94.2)
−0.55 (−6.41; 5.35) 265 (222; 317) 238 235 (98.7) (96.4;
99.7)
−1.26 (−3.64; 0.27) 77.7 (70.4; 85.7)
MMR-RIT-3
240 236 (98.3) (95.8;
99.5)
−1.27 (−3.85; 0.74) 2593 (2350;
2861)
195 175 (89.7) (84.6;
93.6)
−1.40 (−7.47; 4.62) 253 (213; 301) 239 233 (97.5) (94.6;
99.1)
−2.51 (−5.37; −0.97) 68.2 (61.8; 75.3)
MMRII
249 248 (99.6) (97.8;
100)
Reference 2950 (2698;
3224)
192 175 (91.1) (86.2;
94.8)
Reference 268 (224; 320) 249 249 (100) (98.5;
100)
Reference 89.4 (81.4; 98.2)
Abbreviations: MMR, measles-mumps-rubella; N, number of subjects with available results; n (%), number/percentage of subjects who seroconverted; 95% CI, 95% confidence interval; GMC/T, geometric mean
concentrations/titers for measles, mumps, and rubella virus antibodies.
Table 4. Geometric Mean Concentrations (GMCs) for Varicella-Zoster Virus (VZV) Antibodies, and Baseline-Adjusted GMCs and GMCRatios for Antibodies to Hepatitis
A Virus and PCV7 Pneumococcal Serotypes at Day 42 (According-to-Protocol Cohort for Immunogenicity)
Antibody
MMRII MMR-RIT-1 MMR-RIT-2 MMR-RIT-3
N
GMC
(95% CI) N GMC (95% CI) N GMC (95% CI) N GMC (95% CI)
VZV 246 256 (240; 272) 245 246 (229; 263) 238 235 (217; 254) 240 256 (240; 272)
MMRII MMR-RIT-1 MMR-RIT-2 MMR-RIT-3
N
Adjusted
GMC N
Adjusted
GMC
Adjusted GMC ratioa
(95% CI) N
Adjusted
GMC
Adjusted GMC ratioa
(95% CI) N
Adjusted
GMC
Adjusted GMC ratioa
(95% CI)
Hepatitis Avirus 124 42.0 117 33.9 0.81 (0.64; 1.02) 112 39.2 0.93 (0.74; 1.18) 111 39.5 0.94 (0.74; 1.19)
S.PNEU-4 116 3.68 122 3.69 1.00 (0.82; 1.24) 125 3.78 1.03 (0.84; 1.26) 124 3.26 0.89 (0.72; 1.09)
S.PNEU-6B 111 6.50 117 5.86 0.90 (0.75; 1.09) 122 5.87 0.90 (0.75; 1.09) 123 5.81 0.89 (0.74; 1.07)
S.PNEU-9V 120 7.32 121 6.65 0.91 (0.76; 1.08) 125 7.23 0.99 (0.83; 1.17) 127 5.80 0.79 (0.64; 0.94)
S.PNEU-14 118 7.87 127 8.91 1.13 (0.95; 1.35) 127 8.29 1.05 (0.88; 1.26) 126 7.89 1.00 (0.84; 1.20)
S.PNEU-18C 119 6.58 123 6.29 0.96 (0.79; 1.15) 126 6.62 1.01 (0.84; 1.21) 126 5.98 0.91 (0.76; 1.09)
S.PNEU-19F 115 2.39 122 2.41 1.01 (0.83; 1.22) 126 2.52 1.05 (0.87; 1.27) 126 2.33 0.97 (0.80; 1.18)
S.PNEU-23F 113 10.21 121 9.56 0.94 (0.76; 1.16) 127 9.69 0.95 (0.77; 1.17) 126 8.37 0.82 (0.67; 1.01)
Abbreviations: Adjusted GMC, geometric mean antibody concentration adjusted for baseline antibody concentration; MMR, measles-mumps-rubella; N, Number of subjects with both pre- and post-vaccination results
available; 95% CI, 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for baseline concentration - pooled variance with more than 2 groups); S.PNEU, Streptococcus pneumoniae.
aRatio of MMR-RIT lot: MMRII.
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incidence of fever between Days 5 and 12 was 14.8% (95%
CI: 10.9; 19.5) for MMR-RIT-1, 23.3% (18.4; 28.7) for
MMR-RIT-2, 17.3% (13.1; 22.2) for MMR-RIT-3, and
14.8% (10.8; 19.5) for MMRII.
For Days 0–42, incidence of rash of any type varied be-
tween 21.2% and 26.9% across the 4 groups. Measles or
rubella-like rashes were reported in MMR-RIT-1 (n = 6),
MMR-RIT-2 (n = 7), MMR-RIT-3 (n = 5), and MMRII
(n = 9) recipients; varicella-like rash was reported for
MMR-RIT-2 (n = 4) and MMRII (n = 2) subjects. Overall
incidence of parotid-gland swelling was low (Table 5).
There were 2 cases of febrile convulsion during Days
0–42. One MMR-RIT-2 recipient experienced a simple
febrile convulsion at Day 29. This was not considered
vaccine-related by the investigator since the peak preva-
lence of vaccine-related fever, and hence febrile convul-
sions, occurs in the second week following vaccination
with measles-containing vaccines [23].
Table 5. Incidence of Solicited Injection Site (Days 0; 3) and General Symptoms During the 43-Day Post-vaccination Period
(Total Vaccinated Cohort)
Symptom
MMR-RIT-1 (N = 283) MMR-RIT-2 (N = 275) MMR-RIT-3 (N = 283) MMRII (N = 277)
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Days 0; 3
Pain 70 24.8 (19.9; 30.3) 70 25.5 (20.5; 31.1) 79 28.0 (22.9; 33.6) 67 24.5 (19.5; 30.0)
Redness 45 16.0 (11.9; 20.8) 47 17.2 (12.9; 22.1) 41 14.5 (10.6; 19.2) 47 17.2 (12.9; 22.1)
Swelling 20 7.1 (4.4; 10.7) 26 9.5 (6.3; 13.6) 19 6.7 (4.1; 10.3) 15 5.5 (3.1; 8.9)
Days 0; 14
Irritability/fussiness 180 63.6 (57.7; 69.2) 141 51.3 (45.2; 57.3) 150 53.0 (47.0; 58.9) 153 55.2 (49.2; 61.2)
Drowsiness 133 47.0 (41.1; 53.0) 106 38.5 (32.8; 44.6) 113 39.9 (34.2; 45.9) 109 39.4 (33.6; 45.4)
Loss of appetite 111 39.2 (33.5; 45.2) 77 28.0 (22.8; 33.7) 110 38.9 (33.2; 44.8) 94 33.9 (28.4; 39.8)
Fever (rectal temp. 38.0°C) 65 23.0 (18.2; 28.3) 79 28.7 (23.5; 34.5) 64 22.6 (17.9; 27.9) 56 20.2 (15.6; 25.4)
Fever (rectal temp. >39.5°C) 10 3.5 (1.7; 6.4) 7 2.5 (1.0; 5.2) 9 3.2 (1.5; 6.0) 8 2.9 (1.3; 5.6)
Days 0; 42
Fever (rectal temp. 38.0°C) 103 36.4 (30.8; 42.3) 104 37.8 (32.1; 43.8) 104 36.7 (31.1; 42.7) 85 30.7 (25.3; 36.5)
Fever (rectal temp. >39.5°C) 20 7.1 (4.4; 10.7) 14 5.1 (2.8; 8.4) 18 6.4 (3.8; 9.9) 13 4.7 (2.5; 7.9)
Localized/generalized rash 72 25.4 (20.5; 30.9) 74 26.9 (21.8; 32.6) 60 21.2 (16.6; 26.4) 69 24.9 (19.9; 30.4)
Parotid gland swelling 3 1.1 (0.2; 3.1) 3 1.1 (0.2; 3.2) 5 1.8 (0.6; 4.1) 2 0.7 (0.1; 2.6)
Abbreviations: MMR, measles-mumps-rubella; N, number of subjects having received the documented dose; n/%, number/percentage of subjects reporting a specified
symptom; 95% CI, exact 95% confidence interval.
Figure 2. Prevalence of any fever from Day 0 to Day 42 after vaccination (total vaccinated cohort). Abbreviation: MMR, measles-mumps-rubella.
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One MMRII recipient had a complex febrile seizure on
Day 0, which led to hospitalization and the mother’s
withdrawal of the subject from the study; this event, classi-
fied as an SAE, was considered to be related to the study
vaccine.
Of 15 SAEs reported in 11 subjects (Days 0–42), 2 SAEs
were considered to be related to study treatment: febrile
convulsion in a 12-month-old female MMRII recipient
(described above), and idiopathic thrombocytopenic
purpura (onset at Day 20) in a 13-month-old female
MMR-RIT-2 recipient who was hospitalized for treatment
and discharged after 3 days. Both subjects with vaccine-
related SAEs were withdrawn from the study. All SAEs
resolved without sequelae.
Concomitant Medication
Rates of concomitant medication use (Days 0–42) were the
following: MMR-RIT-1 (76.6%), MMR-RIT-2 (72.0%),
MMR-RIT-3 (74.0%), and MMRII (70.1%). Rates of an-
tipyretic medication use were the following: MMR-RIT-1
(65.1%), MMR-RIT-2 (59.2%), MMR-RIT-3 (64.1%),
and MMRII (57.5%).
DISCUSSION
This Phase-2 multicenter exploratory study assessed im-
mune responses to the first dose of MMR-RIT with 3 dif-
fering mumps virus titers and to commercially available
MMRII when concomitantly administered with HAV,
VAR, and PCV7 in healthy children in the United States,
aged 12–15 months. The results indicate that a single
dose of any 1 of the 3MMR-RIT lots elicited an acceptable
immune response with respect to seroresponse rates to
MMR viruses, 42 days post-vaccination. Previous random-
ized comparative studies have shown that MMR-RIT ad-
ministered as a primary vaccination to children in the
second year of life produced similar seroconversion rates
for antibodies to MMR vaccine viruses compared to
those seen with MMRII [24–28].
The current formulation of MMR-RIT used in this
study, when co-administered to young children with
other recommended vaccines (HAV, VAR, and PCV7), elic-
ited measles and rubella virus antibody concentrations
meeting the predefined threshold for seroresponse in
97.5% MMR-RIT recipients, and in 99.6% MMRII
recipients when co-administered with the same vaccines.
Day-42 mumps virus antibody titers after vaccination
with all 3 MMR-RIT lots met the seroresponse threshold
in 90.7%, 90.6%, and 89.7% recipients, respectively,
and no obvious dose–response relationship was observed.
Of note, 13.8% of subjects were seropositive for mumps
at baseline. This high baseline seropositivity rate is likely
attributed to complement enhancement of the mumps
PRN assay rather than prior exposure to mumps or persis-
tence of maternal antibodies. Complement-enhanced
mumps PRN assays have been shown to have higher seror-
esponse rates than unenhanced assays [29], and this may
also be reflected in the baseline seropositivity. Rubella
seroresponse rates across all 4 groups were high (97.5–
100%) and GMCs for antibodies to rubella virus following
all 3 MMR-RIT lots were substantially higher than the
cut-off level of10 IU/mL and would provide effective im-
munization. Long-term follow-up in this study will allow
the evaluation of antibody persistence until approximately
2 years post-vaccination.
The immune response to vaccines routinely co-
administered with MMR dose-1 in the United States
(HAV, VAR, and PCV7) was also assessed. Observed seror-
esponse rates for antibodies to VZV were consistently high
(95.8%) across all 4 treatment groups, and hepatitis
A virus antibody response rates to HAV dose-1 were
83.0% in each group. Furthermore, Day-42 baseline-
adjusted GMCs for antibodies to hepatitis A virus and
Streptococcus pneumoniae serotypes appeared com-
parable when these vaccines were administered with
MMR-RIT or MMRII in this exploratory analysis of
between-group GMC ratios.
MMR-RIT had an acceptable reactogenicity profile
when co-administered with HAV, VAR, and PCV7.
Injection site symptoms at theMMR injection site occurred
in all 4 treatment groups within 4 days of vaccination, al-
though the incidence of severe symptoms was low.
Consistent with previous reports [25–28], vaccination
with MMR-RIT or MMRII was associated with fever (rec-
tal temperature 38.0°C) during the first 2 weeks, which
peaked during days 5–12 after vaccine administration.
MMR-RIT, which contains the Jeryl Lynn–derived RIT
4385 strain, has demonstrated a good reactogenicity pro-
file in previous clinical trials [25–28, 30]. Accordingly, in
this study, a low incidence of other solicited general symp-
toms, including measles/rubella- or varicella-like rash, pa-
rotid gland swelling, and febrile convulsions, was reported
among both MMR-RIT and MMRII recipients during the
follow-up period.
Strengths of this study include use of a computer-
generated randomization list and blinding of study vac-
cines, thereby addressing potential biases in study conduct,
and comparing the immune responses to the study vac-
cine with the US-licensed standard of care (MMRII).
Furthermore, the MMR-RIT formulation used in this
study was free of human serum albumin, thus eliminating
the theoretical risk of microbial contamination associated
with human serum albumin–containing vaccines [14].
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Additionally, omitting a human blood–derived component
from the MMR-RIT formulation might make it more
socially acceptable. Lastly, concomitant administration of
routine vaccines (HAV, VAR, and PCV7) did not affect
the immunogenicity of MMR-RIT and vice versa.
Limitations of the study include the relatively small study
population that is consistent with a Phase-2 planning
study. Larger Phase-3 clinical trials are required in future
to substantiate the immunogenicity and safety profile of
MMR-RIT. Furthermore, extended follow-up studies are
important to evaluate the long-term protection offered by
MMR-RIT.
CONCLUSIONS
This Phase-2 study demonstrated an acceptable immune re-
sponse to 3 candidate MMR-RIT lots containing differing
mumps virus titers with respect to seroresponse rates to all
3 MMR virus components. There was no obvious dose–
response relationship for the 3 mumps virus titers evaluated;
based on the current results, all 3 lots would provide effec-
tive immunization, with an acceptable reactogenicity pro-
file. MMR-RIT can be given concomitantly with HAV,
VAR, and PCV7 without interfering with the immune
response to these co-administered vaccines, as was shown
for MMRII. Confirmatory Phase-3 studies to support
licensure of MMR-RIT on the basis of immunogenic non-
inferiority to the licensed comparator are warranted.
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